亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

作者
Cecília Bonolo de Campos,Umair Munawar,Christina Verbruggen,David S. Scott,Dor David Abelman,Silvia Nerreter,Johanna Lehmann,Seungbin Han,Mariano Arribas,Esther Masih‐Khan,Laura Ann Bruins,Ding Wang,Jeffrey N. Bruce,Zhihua Li,Safa Abdulsalam,Gregory J. Ahmann,Shaji Kunnathu Kumar,Esteban Braggio,Trevor J. Pugh,Rafael Fonseca
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 2178-2178
标识
DOI:10.1182/blood-2025-2178
摘要

Abstract In this study, we investigated tumor intrinsic mechanisms of resistance to cevostamab, a bispecific T-cell engager targeting Fc receptor-like protein 5 (FCRL5) and CD3 that has shown promising clinical activity and durable responses in advanced MM. Longitudinal bone marrow aspirates from nine MM patients treated with cevostamab were analyzed. All patients had previously been treated with both immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI) and eight patients had received daratumumab prior to cevostamab, which was, on average, the 6th line of treatment (mean treatment duration 220±273 days). Five of nine patients responded with ≥PR. Whole genome and transcriptome sequencing was performed on sorted CD138+ MM cells at baseline, and whole exome and transcriptome sequencing was performed on five and three samples, respectively, following cevostamab discontinuation. Baseline FCRL5 expression levels did not correlate with clinical response. However, in one non-responder patient, FCRL5 expression increased four-fold after 28 days of treatment. Given the location of the FCRL5 gene on chromosome 1q—commonly amplified in advanced MM—we evaluated the presence of Gain(1q) in our study cohort. All patients whose best response was ≤PR (n=6) harbored a Gain(1q), whereas it was absent in those who achieved VGPR and sCR (n=3). Crucially, one of the patients that achieved sCR was initially treated with 60 mg of cevostamab for one year and then escalated to a higher dose cohort (90 mg) in the second year. At progression, a clonal FCRL5E115A missense mutation (allelic frequency = 56%) and a subclonal FCRL5G455Efs*19(allelic frequency = 5%) frameshift deletion mutation were detected, both absent at baseline. The missense mutation was located on the extracellular domain of FCRL5 targeted by cevostamab. To validate the functional impact of FCRL5E115Aand FCRL5G455Efs*19 on the sensitivity to cevostamab in vitro, we generated a FCRL5 knockout (KO) model utilizing CRISPR-Cas9 technology in OPM2 MM cells. In vitro cevostamab cytotoxicity assay with PBMCs and pan T cells from healthy donors at various effector to target (E:T) ratios confirmed a complete loss of cevostamab sensitivity in our FCRL5KO models. cDNA encoding patient-derived FCRL5 alterations (FCRL5E115Aand FCRL5G455Efs*19) as well as FCRL5wtwere cloned into mammalian expression vector and reintroduced into FCRL5KO cells. Cevostamab sensitivity was reinstated by FCRL5wt expression in KO cells. In contrast, FCRL5E115A conferred complete resistance to cevostamab (p<0,001) and FCRL5G455Efs*19 depicted a significant decline in cevostamab sensitivity relative to FCRL5wt expressing models. Additional experiment utilizing direct stochastic optical reconstruction microscopy (dSTORM) are ongoing to monitor the membrane localization of FCRL5 mutants. By integrating genomic, transcriptomic and functional data with clinical outcomes, this work is the first to report on acquired FCRL5 mutations causing resistance to cevostamab. We hypothesize that the prolonged treatment duration may have contributed to the acquisition of the target mutations and note a subsequent durable sCR response to BCMA-targeted immunotherapy in the same patient, suggesting immune-related factors such as T cell exhaustion, were not drivers of cevostamab resistance. Due to the limited sample size, these findings require validation in larger cohorts. Nonetheless, our findings begin to elucidate tumor intrinsic mechanisms associated with cevostamab resistance.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
成就马里奥完成签到,获得积分10
刚刚
2秒前
5秒前
纯情的阁发布了新的文献求助10
8秒前
16秒前
深情的从丹完成签到,获得积分10
20秒前
24秒前
阿丕啊呸完成签到,获得积分10
29秒前
32秒前
33秒前
null的应助被伊比利亚的微风采纳,获得10
34秒前
认真的笑卉完成签到,获得积分10
35秒前
43秒前
aba发布了新的文献求助10
49秒前
hamburger完成签到,获得积分10
52秒前
null的应助被等待若魔采纳,获得10
57秒前
陶醉成协完成签到,获得积分10
59秒前
haralee完成签到 ,获得积分10
1分钟前
1分钟前
乐正元正完成签到,获得积分10
1分钟前
时尚的蜜蜂完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
1分钟前
Logan1001发布了新的文献求助10
1分钟前
1分钟前
1分钟前
bkagyin的应助被Logan1001采纳,获得10
1分钟前
hyman发布了新的文献求助10
1分钟前
1分钟前
1分钟前
生动琦完成签到,获得积分10
1分钟前
彩色的可冥完成签到,获得积分10
1分钟前
Logan1001完成签到,获得积分20
2分钟前
2分钟前
从容煜城完成签到,获得积分10
2分钟前
2分钟前
顺利秋天完成签到,获得积分10
2分钟前
甜甜的黑猫完成签到,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158789
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748389
什么是DOI,文献DOI怎么找? 3427080
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354